Articles

It's important to evaluate tear osmolarity during surgical planning to ensure that pre-surgical keratometry readings are not compromised by hyperosmolarity of the ocular surface.

Long-term observational data presented at the 2014 European Society of Retina Specialists (EURETINA) conference support the safety and efficacy profile of the anti-vascular endothelial growth factor (anti-VEGF) agent ranibizumab (Lucentis, Novartis) for the treatment of appropriate patients across its indications

Endoscopic cyclophotocoagulation (ECP) and phacoemulsification cataract extraction, when combined, result in greater reduction of IOP and need for IOP-lowering medications over 3 years compared with cataract extraction by itself.

The European Commission has extended marketing authorization for an intravitreal implant with 700 mcg of dexamethasone in an applicator (Ozurdex, Allergan) for the treatment of adults with visual impairment caused by diabetic macular oedema (DME) who have pseudophakia or whose condition is considered insufficiently responsive to or unsuitable for non-corticosteroid therapy.

A video goggle-based technology may help increase visual acuity (VA) in children with amblyopia.

An international study led by King's College London has identified genetic links to glaucoma.

Dr Omid Kermani discusses his pre-ESCRS diary, highlighting what he believes will be the best bits from the packed programme.

Optimal resistance to in vitro keratolysis by collagenase A can be achieved by collagen crosslinking the deepithelialized anterior corneal surface for 30 minutes, according to a recently published study.

Intracameral cefuroxime can help prevent endophthalmitis after cataract surgery and does so cost-effectively, according to Spanish researchers who conducted a systematic literature review.

Severe obstructive sleep apnoea (OSA) is an important risk factor for developing glaucoma and must be treated in those who have it to improve control of the eye disease, according to new research.

There have been few studies primarily concerned with the relative frequencies and clinical characteristics of cranial neuropathies in diabetic subjects. Here, Dr Stefanucci gives a synopsis of the clinical characteristics and risk factors.

We at OTEurope, wanted to look back over the last 10 years at what has changed over the years. In such a fast-paced industry, there have been monumental strides forward since the launch of this publication.

The international sight-saving charity Orbis has launched an appeal to help eliminate avoidable blindness in Ethiopia.

KalVista Pharmaceuticals has begun a Phase I trial of its plasma kallikrein inhibitor KVD001 for the treatment of diabetic macular oedema (DME).

Advanced DNA testing for congenital cataracts can quickly and accurately diagnose a number of rare diseases marked by childhood blindness, according to a study recently published online.

Researchers examining age-related changes in heparan sulphate (HS) quantity and composition in human Bruch's membrane (BrM) have discovered that the quantity greatly decreases with age, resulting in fewer binding sites for complement factor H (CFH) and affecting the ability of the 402H variant of CFH to bind BrM.

A home-based treatment of amblyopia that incorporated an iPad quickly resulted in improved visual acuity (VA) in the children in whom it was tested, and VA remained stable for at least 3 months after the treatment ended, according to research published online.

Glaucomatous structural damage may affect an individual's ability to divide attention when performing daily tasks such as driving, according to research recently published online.

Aflibercept is effective in inhibiting vascular endothelial growth factor (VEGF) for a prolonged period of time, but possible side effects draw concerns about its long-term use in patients with age-related macular degeneration, diabetic macular oedema and retinal vein occlusion, according to the conclusions of a new study.

The duration and pattern of action of pain-suppressing nonsteroidal anti-inflammatory drugs (NSAIDs) used prior to photorefractive keratotomy (PRK) varies with the NSAID used, according to South Korean researchers.

A fixed combination of brinzolamide 1% and brimonidine 0.2% used twice a day lowers IOP significantly more than either drug alone and is as safe as either, according to results of a 6-month, Phase III study.

Inhibiting thrombin activity may be a treatment option for proliferative vitreoretinopathy (PVR), given that such activity is increased in the vitreous of patients with the disease and is associated with the activation of pro-inflammatory and pro-fibrotic pathways in retinal pigment epithelium (RPE) cells.

The European Commission has approved the eye drop suspension of brinzolamide 10 mg/mL and brimonidine tartrate 2 mg/mL to decrease elevated intraocular pressure (IOP) in adult patients who have open-angle glaucoma or ocular hypertension.

Light-adjustable intraocular lenses (IOLs) provide near-emmetropic refractive outcomes and good uncorrected distance visual acuity that remains stable over time, according to a recent study.

Aganirsen eye drops inhibited corneal neovascularization in patients with keratitis and reduced the need for transplantation in patients who have viral keratitis and central neovascularization, according to a Phase III study of 69 patients.

Acute glaucoma in mice is largely an inflammatory disease, and high intraocular pressure (IOP) causes vision loss by starting an inflammatory response similar to that caused by bacterial infections.

Vasodilators and oral beta-blockers are associated with an increase in the hazard of incidence of early age-related macular degeneration (AMD) and exudative AMD, respectively, according to research recently published online.

Forty potential new treatments for inherited retinal diseases are under development, according to a review by the National Institute for Health Research (NIHR) Horizon Scanning Centre (HSC), working with charitable organization Fight for Sight.

A stable IOL, decreased pseudophacodonesis and improved graft fixation are the benefits of combining Descemet membrane endothelial keratoplasty with glued intrascleral haptic fixation of a posterior-chamber IOL in patients with aphakic or pseudophakic bullous keratopathy, according to recently published research.

Fasting significantly reduces the amount of tears produced by the eye and increases the osmolarity of the tears, according to new research.